Neoadjuvant chemotherapy (NAC), an increasingly used method for breast cancer patients, has the potential to downstage patient tumors and thereby have an impact on surgical options for treatment of the breast and axilla. Previous studies have identified racial disparities in tumor heterogeneity, nodal recurrence, and NAC completion. This report compares the effects of NAC response among non-Hispanic white women and black women in relation to surgical treatment of the breast and axilla.
A retrospective review of 85,303 women with stages 1 to 3 breast cancer in the National Cancer Database who received NAC between 1 January 2010 and 31 December 2016 was conducted. Differences in sociodemographic and clinical variables between black patients and white patients with breast cancer were tested.
The study identified 68,880 non-Hispanic white and 16,423 non-Hispanic black women who received NAC. The average age at diagnosis was 54.8 years for the white women versus 52.5 years for the black women. A higher proportion of black women had stage 3 disease, more poorly differentiated tumors, and triple-negative subtype. The black women had lower rates of complete pathologic response, more breast-conservation surgery, and higher rates of axillary lymph node dissection, but fewer sentinel lymph node biopsies. Axillary management for the women who were downstaged showed more use of axillary lymph node dissection for black women compared with sentinel lymph node biopsy.
The black patients were younger at diagnosis, had more advanced disease, and were more likely to have breast-conservation surgery. De-escalating axillary surgery is being adopted increasingly but used disproportionately for white women.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Fahad Ullah M. Breast cancer: current perspectives on the disease status. In: Ahmad A (ed) Breast Cancer Metastasis and Drug Resistance: Challenges and Progress. Advances in Experimental Medicine and Biology. Springer International Publishing, Cham, Switzerland, 2019, pp 51–64. doi:https://doi.org/10.1007/978-3-030-20301-6_4.
Iqbal J, Ginsburg O, Rochon PA, Sun P, Narod SA. Differences in breast cancer stage at diagnosis and cancer-specific survival by race and ethnicity in the United States. JAMA. 2015;313:165–73. https://doi.org/10.1001/jama.2014.17322.
Williams DR, Mohammed SA, Shields AE. Understanding and effectively addressing breast cancer in African American women: unpacking the social context. Cancer. 2016;122:2138–49. https://doi.org/10.1002/cncr.29935.
Hill DA, Prossnitz ER, Royce M, Nibbe A. Temporal trends in breast cancer survival by race and ethnicity: a population-based cohort study. PLoS ONE. 2019;14(10). https://doi.org/10.1371/journal.pone.0224064.
Kohler BA, Sherman RL, Howlader N, et al. Annual report to the nation on the status of cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. J Natl Cancer Inst. 2015;107:djv048. doi:https://doi.org/10.1093/jnci/djv048.
Yedjou CG, Sims JN, Miele L, et al. Health and racial disparity in breast cancer. Adv Exp Med Biol. 2019;1152:31–49. https://doi.org/10.1007/978-3-030-20301-6_3.
Wheeler SB, Spencer JC, Pinheiro LC, Carey LA, Olshan AF, Reeder-Hayes KE. Financial impact of breast cancer in black versus white women. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:1695–701. https://doi.org/10.1200/JCO.2017.77.6310.
Siddharth S, Sharma D. Racial disparity and triple-negative breast cancer in African-American women: a multifaceted affair between obesity, biology, and socioeconomic determinants. Cancer. 2018;10(12). https://doi.org/10.3390/cancers10120514.
Cain H, Macpherson IR, Beresford M, Pinder SE, Pong J, Dixon JM. Neoadjuvant therapy in early breast cancer: treatment considerations and common debates in practice. Clin Oncol. 2017;29:642–52. https://doi.org/10.1016/j.clon.2017.06.003.
Graham PJ, Brar MS, Foster T, et al. Neoadjuvant chemotherapy for breast cancer: is practice changing? A population-based review of current surgical trends. Ann Surg Oncol. 2015;22:3376–82. https://doi.org/10.1245/s10434-015-4714-x.
Knisely AT, Michaels AD, Mehaffey JH, et al. Race is associated with completion of neoadjuvant chemotherapy for breast cancer. Surgery. 2018;164:195–200. https://doi.org/10.1016/j.surg.2018.03.011.
Walsh SM, Zabor EC, Stempel M, Morrow M, Gemignani ML. Does race predict survival for women with invasive breast cancer? Cancer. 2019;125:3139–46. https://doi.org/10.1002/cncr.32296.
Fayanju OM, Ren Y, Suneja G, et al. Nodal response to neoadjuvant chemotherapy predicts receipt of radiation therapy after breast cancer diagnosis. Int J Radiat Oncol Biol Phys. 2020;106:377–89. https://doi.org/10.1016/j.ijrobp.2019.10.039.
Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project protocols B-18 and B-27. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:778–85. https://doi.org/10.1200/JCO.2007.15.0235.
Gu J, Groot G, Boden C, Busch A, Holtslander L, Lim H. Review of factors influencing women’s choice of mastectomy versus breast conserving therapy in early-stage breast cancer: a systematic review. Clin Breast Cancer. 2018;18:e539–54. https://doi.org/10.1016/j.clbc.2017.12.013.
Franceschini G, Di Leone A, Natale M, Sanchez MA, Masett R. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer. Ann Ital Chir. 2018;89:290.
National Cancer Database. American College of Surgeons. Retrieved 16 September 2020 at https://www.facs.org/quality-programs/cancer/ncdb.
Pastoriza JM, Karagiannis GS, Lin J, et al. Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer. Clin Exp Metastasis. 2018;35:613–23. https://doi.org/10.1007/s10585-018-9932-8.
Killelea BK, Yang VQ, Wang S-Y, et al. Racial differences in the use and outcome of neoadjuvant chemotherapy for breast cancer: results from the National Cancer Database. J Clin Oncol Off J Am Soc Clin Oncol. 2015;33:4267–76. https://doi.org/10.1200/JCO.2015.63.7801.
Chavez-MacGregor M, Litton J, Chen H, et al. Pathological complete response in breast cancer patients receiving anthracycline and taxane-based neoadjuvant chemotherapy: evaluating the effect of race/ethnicity. Cancer. 2010;116:4168–77. https://doi.org/10.1002/cncr.25296.
Tichy JR, Deal AM, Anders CK, Reeder-Hayes K, Carey LA. Race, response to chemotherapy, and outcome within clinical breast cancer subtypes. Breast Cancer Res Treat. 2015;150:667–74. https://doi.org/10.1007/s10549-015-3350-2.
Richardson LC. Patterns and trends in age-specific black-white differences in breast cancer incidence and mortality–United States, 1999–2014. MMWR Morb Mortal Wkly Rep. 2016;65(40). https://doi.org/10.15585/mmwr.mm6540a1.
Akinyemiju TF, Vin-Raviv N, Chavez-Yenter D, Zhao X, Budhwani H. Race/ethnicity and socioeconomic differences in breast cancer surgery outcomes. Cancer Epidemiol. 2015;39:745–51. https://doi.org/10.1016/j.canep.2015.07.010.
Kish JK, Yu M, Percy-Laurry A, Altekruse SF. Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in Surveillance, Epidemiology, and End Results (SEER) registries. JNCI Monogr. 2014;2014:236–43. https://doi.org/10.1093/jncimonographs/lgu020.
Vona-Davis L, Rose DP. The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health. 2009;18:883–93. https://doi.org/10.1089/jwh.2008.1127.
Moo T-A, Sanford R, Dang C, Morrow M. Overview of breast cancer therapy. PET Clin. 2018;13:339–54. https://doi.org/10.1016/j.cpet.2018.02.006.
Boughey JC, Suman VJ, Mittendorf EA, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial. JAMA. 2013;310:1455–61. https://doi.org/10.1001/jama.2013.278932.
Kuehn T, Bauerfeind I, Fehm T, et al. Sentinel lymph node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol. 2013;14:609–18. https://doi.org/10.1016/S1470-2045(13)70166-9.
Mamtani A, Barrio AV, King TA, et al. How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study. Ann Surg Oncol. 2016;23:3467–74. https://doi.org/10.1245/s10434-016-5246-8.
McLaughlin SA, Wright MJ, Morris KT, et al. Prevalence of lymphedema in women with breast cancer 5 years after sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:5220–6. https://doi.org/10.1200/JCO.2008.16.3766.
Meeske KA, Sullivan-Halley J, Smith AW, et al. Risk factors for arm lymphedema following breast cancer diagnosis in black women and white women. Breast Cancer Res Treat. 2009;113:383–91. https://doi.org/10.1007/s10549-008-9940-5.
The National Cancer Database (NCDB) is a joint project of the Commission on Cancer (CoC) by the American College of Surgeons and the American Cancer Society. The NCDB of the CoC and the hospitals participating in the NCDB of the CoC are the source of the de-identified data used in this study. They have not verified and are not responsible for the statistical validity of the data analysis or the conclusions derived by the authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Relation, T., Obeng-Gyasi, S., Bhattacharyya, O. et al. Racial Differences in Response to Neoadjuvant Chemotherapy: Impact on Breast and Axillary Surgical Management. Ann Surg Oncol (2021). https://doi.org/10.1245/s10434-021-09657-w